Epilepsy Drug Sulthiame Shows Promise in Treating Sleep Apnea

Clinical trials reveal sulthiame significantly reduces breathing pauses and daytime sleepiness in obstructive sleep apnea patients.

Patients on the highest dose of sulthiame experienced nearly a 40% reduction in apnea-hypopnea index over 15 weeks.
Sulthiame improved oxygen levels in the blood and decreased daytime sleepiness among participants.
The trial included 298 patients who could not tolerate CPAP machines, offering a potential alternative treatment.
Mild to moderate side effects such as headache and fatigue were reported by some participants.
Further studies are needed to confirm long-term effectiveness and safety.